Search PubMed⌕ Search

Biomedical subjects

J Taseski

Publications and source records attributed to J Taseski.

At least 37 records · Page 2Linked to original sources
PubMedDate not supplied

Plasma exchange in myasthenia gravis and multiple sclerosis.

During the last twenty-year period therapeutic plasma exchange (TPE) was used in the treatment of 68 patients with myasthenia gravis and 61 patients with multiple sclerosis. The therapeutic effects were evaluated on the basis of neurologic deficit changes, electrophysiological findings, necessary laboratory analyses and patient's general conditions. It was shown that the therapeutic effects mosty depended on the nature and stage of the basic disease, adequate selection of the patients and timely applied therapeutic procedure. Significant positive effects of the TPE treatment applied with the anti-inflammatory and immunosuppressive therapy were observed in patients with myasthenia gravis and multiple sclerosis upon clinical findings and some paraclinical tests.

Adolescent↗
PubMedDate not supplied

[Blood transfusion therapy at the Military Medicine Academy--present possibilities].

Blood component therapy refers to the transfusion of the specific part of blood that a patient needs, as opposed to the routine transfusion of whole blood (WB) in the past. This not only maintains blood resources, but also provides the optimal method of transfusing patients who require large amounts of a specific blood component. Since this concept have been accepted, the Institute of Transfusiology of Military Medical Academy (MMA) possess appropriate equipment for blood collection and processing of WB in components. Mainly, all kind (except frozen) of packed red cells (RBCs), platelet concentrates (random-donor buffy coat or apheresis donation), single-donor (apheresis) or random-donor (buffy coats) granulocytes, fresh frozen plasma (FFP), single-donor cryoprecipitate are prepared. Recently, fibrin glue (obtained by recycled cryoprecipitation from single-donor or autologous plasma), and some of new generation of blood components: hematopoietic stem and progenitor cells (fresh or cryopreserved), collected from bone marrow or harvested from peripheral blood after mobilization and donor-specific mononuclear cells for cell therapy, i.e. immunomodulation during relapse of leukemia after bone marrow transplantation, have become the routine. Analysis of blood component therapy done at the MMA during the past 11 years (1989-1999) showed that: a) participation of WB transfusion in the group of surgical clinics was permanently decreased (from 59.60% in 1989 to 0.37% in 1999); b) WB transfusion (in the last few years) practically was not used in the group of internal medicine clinics (0.82% in 1993 and 0.45% in 1999); c) overall WB transfusion in MMA is extremely rare (0.37%).

Blood Component Removal↗
PubMedDate not supplied

[Biochemical changes in thrombocyte concentrates stored for 5 days].

The purpose was to evaluate biochemical and functional changes in platelet concentrates prepared from buffy-coat (PC-BC), stored up to five days at temperature of 20 +/- 2 degrees C. Forty-two PC-BC units from random blood donors were examined. In order to determine the biochemical changes we studied the release of lactate dehidrogenase (LDH), changes in pH value, pCO2, pO2, glucose and lactate concentrations. In addition, the aggregation of platelets with adenosine diphosphate (ADP), and hypotonic shock response were examined. The concentration of LDH markedly increased from 138.8 IU/l (day 1st) up to 234 IU/l (day 5th). The lactate concentration increased significantly (p < 0.001) from 2.1 to 8.6 mmol/l, and consequently pH decrease was observed (from 7.31 to 7.13). The level of glucose decreased gradually from 22.8 to 19.4 mmol/l. The pCO2 decreased progressively from 36.8 mmHg to 24 mmHg during first two days of storage and after that gradually to 20 mmHg. In contrast, pO2 fluctuated between 108 and 133 mmHg during five day of storage. Recovery of hypotonic shock response was 70% on day 1st and 35.7% on day 5th, respectively (p < 0.001). Platelet aggregation using ADP showed significant increase from 6.6 sec (day 1st), to 11.2 sec (day 4th) and 14.6 sec (day 5th), too. Significant differences in biochemical parameters and platelet functions, with confirmed relationship between changes obtained during five days stored PC-BC did not affect the efficacy of applied platelets.

Blood Platelets↗
PubMedDate not supplied

[Significance of blood transfusion in the development of cytotoxic antibodies in patients on hemodialysis].

The aim was to evaluate the influence of red blood cells (RBC) transfusion on the development of cytotoxic antibodies (C-Ab) in patients subjected to hemodialyses (HD) and planned for the kidney transplantation. The group of 71 HD patients, of mean age 42 years (19-65), 48 males and 23 females, planned for the kidney information was examined. Out of 71 HD patients, only 42 (59.19%) HD patients (group I) received subcutaneously recombinant human erythropoietin--rhuEPO (Eprex--epoetin-alpha or Recormon SE--epoetin-beta in dosage of 4,000 IU during every HD; i.e. one to three times a week) and they were not treated by RBC transfusion. The other 29 (40.85%) HD patients (group II) received RBC transfusion: 18 (62.07%) HD patients received < 10 units 18 of RBC, 8 (27.59%) HD patients received 10-20 units of RBC; 3 (10.35%) HD patients received > 20 units of RBC. Testing of C-Ab was done in all patients every three months by standard lymphocytotoxicity test on the panel from 20 different lymphocyte donors with definite class I phenotype of antigen HLA. C-Ab was not found in HD patients who were not treated by RBC transfusion. Out of 18 HD patients who received < 10 units of RBC only 3 (16.67%) HD patients developed C-Ab; out of 8 HD patients who received 10-20 units of RBC, in 4 (50%) patients was proved C-Ab; and C-Ab was proved in all 3 HD patients who received > 20 units of RBC. RhuEPO administration is very important for the transfusiologic treatment of HD patients; especially those who are planned for the kidney transplantation. Development of C-Ab is in direct correlation with the number of transfunded units of RBC. HD patients who received 10 or more units of RBC were at great risk to develop C-Ab.

Adult↗
PubMedDate not supplied

[Advantages of polyethylene glycol in comparison to bovine serum albumin in the indirect antiglobulin test in pregnant women].

Results of indirect antiglobulin test (IAT) adding polyethylene glycol (PEG) were compared with conventional IAT performed using bovine serume albumin (BSA) with the aim of prenatal protection of Rh(D) negative pregnant women. Investigation enrolled 986 samples of pregnant women sera and confirmed that the use of PEG-IAT increased the degree of detection of clinically significant antierythrocyte antibodies. Above all, form the Rhesus blood groups system (using exclusively PEG-IAT) was detected by one antibody of anti-D, anti-C, anti-e and two anti-E), while by using BSA, anti-e was not detected at all. Besides, the need for additional serologic techniques has been reduced (treating of erythrocytes by enzymes) and the work of laboratories for prenatal protection has been alleviated, and at the same time the quality of analyses was not diminished, which gave the preference to PEG-IAT compared to BSA-IAT in prenatal testing.

Coombs Test↗
PubMedDate not supplied

[Detection of anti-HCV antibodies in patients on long-term hemodialysis].

Hepatitis C virus (HCV) infection is highly prevalent among chronic dialysis patients and is the most common cause of chronic liver disease. Ninety six patients on chronic hemodialysis in our institute of transfusiology at the Military Medical Academy were evaluated for the presence of HCV infection. There was a significant relationship between presence of anti-HCV antibodies and number of blood transfusion received by examined patients. We concluded that hepatitis C is a common problem among patients on chronic hemodialysis in our institution: HCV infection is proved in about 48.95% of all patients on hemodialysis.

Adult↗
PubMedDate not supplied

Donor leukocyte infusion--the effect of mutual reactivity of donor's and recipient's peripheral blood mononuclear cells on hematopoietic progenitor cells growth.

Donor leukocyte infusions are an effective therapy for patients who relapse with leukemia after bone marrow transplantation. We report the case of 14-year-old boy who relapsed 34 months after sibling donor bone marrow transplant for Philadelphia-positive chronic myeloid leukemia. Subsequently, he received three infusions of donor mononuclear cells (DMNC) harvested in steady state hematopoiesis and one G-CSF mobilized-peripheral blood mononuclear cells (PBMC) infusion. Simultaneously, test named as--"Test of Mixed Progenitors" (TMP) was performed for the assessment whether the outcome of donor leukocyte infusion treatment could be predicted. Prior to DMNC infusions, the CFU-GM and BFU-E colony assays were performed for donor's and recipient's PBMC individually, as well as for the mixture of these cells at 1:1 ratio. The cells were plated either directly in the semisolid medium or after 24 h preincubation treatment. Significantly lower values for CFU-GM derived colonies were determined in TMP in comparison to the CFU-GM values obtained for the recipient's cells. The reduced number of CFU-GM was determined both in TMP performed without preincubation treatment, app. 80% and after the 24 h preincubation, app. 55%. The reduced number of BFU-E derived colonies (app. 44%) was observed only related to recipient's cells and after the preincubation treatment of the cells. The patient did not develop GVHD and currently (40 months after the first infusion). He remained well in complete hematological, cytogenetic, molecular and clinical remission, which was the most direct evidence of the GVL effect. The novel in vitro TMP test in which the specific contribution of donor's leukocytes to the growth of recipient's hematopoietic precursor cell growth was determined, correlated with the clinical outcome.

Adolescent↗
PubMedDate not supplied

Locally produced specific cytomegalovirus immunoglobulin for intramuscular use as a therapy in renal allograft recipients.

Immunomodulator, i.e. specific hyperimmune anticytomegalovirus immunoglobulin for intramuscular administration, produced in 1999 with the aim of prevention of CMVI, and the development of the disease, was for the first time applied in kidney transplant recipients in January 2000, in the Center for kidney transplantation at the Military Medical Academy. Therapy was administered in four cytomegalovirus (CMV)--seronegative kidney recipients from CMV-seropositive donors--the combination that in the majority of cases lead to the development of CMVI/disease resulting in transplant rejection. Patients received 0.2-0.3 ml/kg of cytomegalovirus immunoglobulin (CMVIG) 6 hours before the transplantation, and subsequently the same dose during the following 5 weeks. Simultaneously, they received ganciclovir in therapeutic doses adjusted according to creatine clearance during the first three post-transplantation months (2 weeks parenterally, the rest orally). Kidney transplant recipients tolerated well i.m. applied CMVIG without any adverse effects. Test result obtained from the Paul-Erlich Institute, Germany in 1999 spoke in favor of the quality of the first national CMVIG preparation.

Antibodies, Viral↗